ABOUT

Aurora Life Sciences (ALS) is dedicated to empowering diagnostics, providing life changing discoveries and enabling healthier decisions.

Established in 2010, with an expertise in biophotonics and microarray technologies, ALS set out to enhance wellness testing with a focus on developing an innovative multiplexed autoimmune testing platform. The ALS Autoimmune 30+ panel achieves this by providing an extensive set of autoimmune disease markers in one test. This innovative, cost effective and time sensitive diagnostic tool provides an expanded overview of an individual’s autoimmune status.

Laboratory

Certificate of Compliance from Centers for Medicare & Medicaid Services (CMS) in 2016, Clinical Laboratory Improvement Amendments (CLIA) # 14D2101443

College of American Pathologists (CAP) Proficiency testing

Innovative patented technology

Highly trained staff

Technology

Patients and practitioners are dependent on information from quality laboratory testing. At ALS we continually strive to offer tests that are accurate, reproducible and functionally relevant.

Our testing platform utilizes a patented fluorescence imaging system for the  detection and identification of autoimmune disease markers based on the principle of immunoassay. Each patient’s test panel contains antigens, calibrators and controls. Autoimmune disease markers (autoantibodies), if present in the blood sample, bind to the corresponding specific antigen(s) within the assay. Bound autoantibodies are then detected by incubation with a fluorophore labeled conjugate and are read on the fluorometer imaging system. Results are provided in an easy to interpret format.

Meet the Team

President

Dan Nagle

Formally trained in optical and mechanical engineering, Dan Nagle has extensive experience in the field of biophotonics. He secured an exclusive license from Argonne National Laboratory utilizing patented laser based microarray optical imaging technology. This license lead him to start a company integrating this technology together with disease marker assays furthering the evolution of healthcare through empowering diagnostic screening to be more comprehensive, informative and affordable.

Vice President

Dennis Dougherty

Formally trained in electrical and mechanical engineering, Dennis Dougherty entered the world of biotechnology with the launch of an ultra-compact high speed biochip microarray reader. This initial exposure to the world of healthcare led Dennis to advocate for improved and more cost effective systems to aid in the earlier diagnosis of disease risk as medical care evolves from a disease based to a prevention based healthcare system.

Chief Medical Advisor

Roger L Greenlaw, M.D. FACP/G ABHIM

Dr. Greenlaw is board certified in Internal Medicine, Gastroenterology and by the American Board of Holistic Integrative Medicine. He is a member of the American Medical Association, the American College of Lifestyle Medicine and believes lifestyle related chronic disease is preventable and reversible through therapeutic lifestyle change. Educated self-care is the new primary care and his research in lifestyle medicine has resulted in publication of several articles in peer-reviewed journals.

Laboratory Director

Roger D. Hilbert, M.D.

Dr. Hilbert, is a board certified Pathologist and an active member of several professional organizations including: The American Medical Association, American Society of Clinical Pathologists, College of American Pathologists, America’s Blood Centers, A. James French Pathology Society and the American Association of Blood Banks.